WO1988006043A1 - Precipitation de collagene sous forme de tactoides - Google Patents

Precipitation de collagene sous forme de tactoides Download PDF

Info

Publication number
WO1988006043A1
WO1988006043A1 PCT/AU1987/000038 AU8700038W WO8806043A1 WO 1988006043 A1 WO1988006043 A1 WO 1988006043A1 AU 8700038 W AU8700038 W AU 8700038W WO 8806043 A1 WO8806043 A1 WO 8806043A1
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
producing
product
precipitate
solution
Prior art date
Application number
PCT/AU1987/000038
Other languages
English (en)
Inventor
John Francis Bateman
John Alan Maurice Ramshaw
David Edward Peters
Peter Archibald Tulloch
Original Assignee
The University Of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Melbourne filed Critical The University Of Melbourne
Priority to BR8707660A priority Critical patent/BR8707660A/pt
Priority to BR8707169A priority patent/BR8707169A/pt
Priority to PCT/AU1987/000038 priority patent/WO1988006043A1/fr
Publication of WO1988006043A1 publication Critical patent/WO1988006043A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/14—Powdering or granulating by precipitation from solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
    • C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2389/00—Characterised by the use of proteins; Derivatives thereof
    • C08J2389/04—Products derived from waste materials, e.g. horn, hoof or hair
    • C08J2389/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin

Definitions

  • This invention relates to collagen products.
  • this invention relates to col lagen products made from soluble col lagen.
  • a new method by which soluble collagen can be formed into quasi- crystalline structures by precipitation using soluble polymers is described.
  • the use of an aggregate of this quasi- crystalline collagen to form a variety of collagen materials which have improved properties compared with existing collagenous materials is described.
  • Collagen is an extremely common protein in the animal kingdom and therefore many uses for products based upon collagen have developed. Many products use collagen in either its native form (i.e.
  • Native collagen is used for various products such as in the production of leather from animal skins, or such as the production of sausage casings in which the col lagen is finely divided and reformed into the desired structure.
  • collagen and for items made from collagen in medical fields such as in artificial arteries, veins, tendons, corneas, heart valves, skin, or patches or the like which are used as replacement parts for disease or injury affected parts in humans, or in cosmetic applications such as mammary prostheses or injectable collagen, or in collagen sponges, sutures or haemostat materials which may be used during surgery or in the treatment of disease (Chvapil, 1979).
  • medical products made from collagen are at present unsatisfactory because of an inability to reproduce the native structure, composition or strength which exists in the norma l collagenous tissue or because of the immune response el icited by the presence of immunogenic co l l agen or components or other material foreign to the body.
  • col lagen exists in many types and in the most common of these types, col l agen e xi sts a s f ibr i l s i n which indi v i du a l co l l a g en mo l ecu l e s are arran ged in a s ta gger ed o v er l ap structure (Bornstein and Traub, 1979).
  • telopeptides lead to an antigenic response in humans; collagen lacking telopeptides is relatively non antigenic (Linsenmayer, 1982) but can stil l be made to form fibrils.
  • Materia l s f ormed by fibril regeneration are of ten too hydrated and additional methods such as freezedrying or cell-induced contraction must be used to give a functional product.
  • Other non-native fibrous aggregates termed FLS collagen, can be formed in which the collagen molecules are arranged in various staggered arrangements with the orientation of the molecules in both directions.
  • Quasi-crystal line aggregates can also be formed. These include very small crystallites of collagen, termed SLS collagen, in which the collagen molecules all have the same orientation, but there is no stagger between molecules. These have been of partial use in deducing the native structure of collagen but SLS collagen has been of little use in the manufacture of larger structures l ike biomedica l products.
  • quasi- crystal line tactoids of col lagen can be prepared, using conditions simil ar to those used f or reconstitutin g fibrils by heat gelation (Leibovich and Weiss, 1970; Lee and Piez, 1983) but the technique of production is more dif ficult than the technique described here as it does not inv o l v e simp l e precipitation.
  • the collagen is arranged in a staggered form similar to native fibrils.
  • the t actoid s ar e produced by a new procedure , precipitation by soluble, neutral polymers.
  • collagen is precipitated by other procedures, for example salts , alcohols or heat, amorphous precipitates are formed.
  • the present invention provides a method of producing a collagen product comprising forming an aqueous solution containing dissolved collagen and a water soluble or miscible polymer adapted to precipitate the collagen out of solution in the form of tactoids.
  • the pH of the said solution is pref erably 3.5-10 more preferably 5-8 with 7-8 being still more preferred and about 7.5 being most preferred.
  • the collagen precipitate may be left in the form of a paste or slurry and used in this f orm or afte r concentration by any one of the methods gravitational precipitation, filtration, centrifugation or the like.
  • the precipitate may be crosslinked, tanned or stabilised by one or more of chemical, physical or biochemical methods either bef ore or af ter it has been concentrated . Crosslinking, tanning or stabilisation applied to the precipitate bef ore concentration makes the tactoids resistant to def orming actions such as heating, pressure or biochemical degradation.
  • the so precipitated collagen may also be f ormed, for example, into a synthetic body part.
  • f orming into a synthetic body part may be effected by gravitational precipitation, f iltration, centifugation , moulding, pressing, shaping or any other way or combination of ways.
  • Shapes which may be prepared include sheets, tubes, strings and rods. It has been found particularly desirable to form the so precipitated collagen into sheets for use as synthetic dressings for wounds and into tubes for use as synthetic tubular body parts.
  • the sheets can be formed by centrifugation in a large basket centrifuge or the like or by gravitational precipitation or filtration. Other methods of producing the sheets are also possible. A more compacted sheet is produced by centrifugation in comparison with gravitational precipitation or filtration. Tubes can also be prepared by centrifugation or by casting, mou l ding or shaping. T he c o l l a g en m a y b e p r e c i p i t a t e d o n t o a suitable substrate to form a composite material.
  • Such a substrate, onto which the col lagen is precipitated may ha ve the form of a particular body part or biomedical product.
  • the substrate may take the form of a matrix.
  • the substrate may take the f orm of a plastic or other synthetic surf ace in the f orm of a sheet, tube or mesh, onto which the col l agen is directly deposited forming a col lagenous coating.
  • the substrate may a l so take the f orm of a composit e, f or e x amp l e , v ar ious s y nth et ic l a y er s b onded to a n artificial ly or natural ly-produced matrix.
  • g l utara l dehyde or similar chemicals may be used to stabilise the matrix.
  • the col lagen of the present invention may be used as a paste or sl urry.
  • Such a paste or sl urry wou l d ha v e a number of applications including as an impl ant material such as in t h e f o rm of a n i n j e c t a b l e me di um f or u s e i n co sme t ic surgery.
  • Such a slurry may be stabilized chemically such as by g l utara l dehyde or irradiation. Such as with gamm a radiation.
  • the concentration of this tactoidal col lagen in the paste or sl urry is pref erab l y not l ess than 10 mgm/ml, more preferably not less than 30 mgm/ml and most preferably not less than 40 mgm/ml.
  • the col lagen useful for forming the col lagen products of this invention inc ludes col lagen derived from hides , skins or other col lagen containing organs or tissues of humans or other vertebrates or invertebrates and include s co l l agens of one type or mixtures of types. So lub le co l l agen can be prepared by enzymic treatment of col l agen from those sources. Suitable enzymes include pepsin.
  • the col l agen may a l so be deri ved f rom the cu l ture medium of cel ls, tissues or organs grown in cel l- or tissue- culture.
  • the culture medium used to produce the col lagen may be a cu l ture medium f rom ce l l or tissue cu l ture deri v ed f rom a person f or whom a synthetic body part is to be produced; it is believed that doing this will substantial ly reduce the likel ihood of rejection.
  • a substrate may be introduced into the culture medium such that collagen and other components will be directly produced thereon. Such a substrate may have the form of a particular body part or biomedical product desired.
  • the substrate may take the form of a matrix.
  • the substrate may take the form of a plastic or other synthetic surface in the form of a sheet, tube or mesh, onto which the collagen and other components are directly deposited forming a collagenous coating.
  • the substrate may be formed from aggregates of tactoidal collagen of this invention.
  • the water soluble or miscible polymer is preferably a neutral polymer.
  • Such polymers may be at least one of the synthetic polymers polyvinyl alcohol, polyethylene oxide, polyvinylpyrrolidinone, polyacrylamide, polyethylene glycol, polypropylene glycol, polyvinyl methyl ether, maleic anhydride copolymers and the like; or at least one of the modified, natural, neutral polymers hydroxyethyl starches, methyl cel lulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose or the like; or at least one of the natural neutral polymers agarose, dextrins , dextrans, starches , pectins , alginates and the like.
  • Such standing is ef f ected at temperatures between the denaturation temperature of the col l agen and th e freezing point of the solution; preferably at between zero and 20°C; more preferably between zero and 10°C.
  • These added materials may also be incorporated into the solution of soluble col lagen before addition of the polymer or otherwise incorporated into materia l made f rom the col l agen.
  • Charged, water soluble or water miscible polymers may be used as part of a mixture with the neutral polymer or polymers and added to the soluble col lagen with the neutral polymer sol ution. These charged polymers may be used to modify the properties of the soluble collagen solution or the material made from the precipitated collagen.
  • the co l l agen product o f this in v ention may be chemica l l y or biochemica l l y stabi l ised.
  • Biochemica l stabilisation may be ef f ected by enzymes such a s lysyl oxidase. Chemical stabilisation may be effected by tanning agents, syntans, other cross-linking agents or chemica l modif iers of co l l a gen. Of particu l a r interest are stabilisers which limit proteolysis or the immunogenicity of the co l l agen. Glutaraldehyde is a stabiliser of particular interest . The product may also be stabilised by dehydration by mild heat, water miscible sol vents, critical point drying or the like. Such stabilisation may be performed before or after a shaping operation.
  • the col lagen product of this invention may be sterilised chemically or by irradiation.
  • Chemical sterilisation may be conducted by means of suitable solutions of sterilising materials such as glutaraldehyde from between 0.5% to 5% concentration.
  • the product may be stored in solutions of sterilant until required f or use.
  • Steri lisation by means of irradiation can be conducted by exposing the col lagen product of this invention to gamma rays from a suitable source. From 0.5 to 5 Mrads of irradiation may be used, preferably 2.5 Mrads of gamma ray irradiation is suitable for satisfactory sterilisation of the product.
  • the tactoids formed by precipitation of the soluble col lagen in this invention are useful in production of synthetic body parts, and other materials for medical or veterinary applications.
  • the collagen tactoids or tactoid assemblages could be stabilised by chemical or biochemical techniques or could be formed into various useful shapes and then stabilised.
  • the tactoidal collagen has potential application in many areas such as the manufacture of collagen sponges or haemostatic agents , of dressings, of membranes, of skin, of tubes and the like and in the treatment of disease such as peridontal disease.
  • the tactoida l collagen can also be used in conjuction with other structural type materials to form composite materials with diff erent properties.
  • a tube of tactoidal collagen can be covered with a woven or knitted mesh of fibre such as Dacron to give the tube additional strength.
  • the tactoidal collagen can be formed into a tube surrounding the mesh to give a more intimate contact with the mesh and better properties.
  • the tactoids in a preferred orientation by the application of an electric field or by means of mechanical action. Materials made from the oriented tactoids may have beneficial effects in the healing of wounds. Many other methods of utilising the tactoidal collagen in a variety of shapes and forms and in conjuction with diverse other materials can be envisaged.
  • the product of this invention also has application in areas outside medical and veterinary products including plastics, fabric, leather or as composites or the like.
  • the col l agen products of this in v ention ha ve advantages over presentl y avail abl e products. These include, low immunogenicity, ease of preparation, high collagen content, and strength.
  • the fol lowing examples il lustrate the invention.
  • Type I collagen was solubilised and extracted from f oeta l ca l f skin by pepsin digestion and purif ied b y fractional salt precipitation according to the method of Trelstad et al.(1967).
  • This purified collagen was dissol ved in 200 mM Tris-HCl buffer pH 7.5 at 4°C and at a concentration of 10 mg/ml.
  • Polyethylene glycol (PEG) 4000 was than added to produce a final concentration of 2.5% (w/v).
  • a precipitate of tactoidal collagen formed which settl ed to the bottom of the container af ter standing at 4 ° C f or a few hours or could be concentrate d by filtration or centrifugation.
  • EXAMPLE 2 As for Example 1 except that the concentration of the collagen was 1 mg/ml.
  • EXAMPLE 3 As for Example 2 except that PEG 400 to a final concentration of 3.5% (w/v) was used to precipitate the collagen.
  • EXAMPLE 4 Type III collagen, solubilised and extracted as in Example 1 , was dissolved at a concentration of 1 mg/ml in 200mM Tris- HCl buffer pH7.6 at 4°C. PEG 400 was added to the solution to a final concentration of 4.0% (w/v) and the precipitate of tactoidal collagen formed.
  • EXAMPLE 5 As for Example 4 except that a final concentration of 2.5% (w/v) PEG 4000 was used.
  • EXAMPLE 6 Type II collagen was isolated by the method of Trelstad et al. (1976) from bovine articular cartilage by pepsin solubilisation and fractional salt precipitation. The purified type II collagen was dissolved in 200 mM Tris- HCl buffer at pH 7.6 at 4°C and at a concentration of 1 mg/ml. PEG 400 was then added to produce a final concentration of 3.0% (w/v). The precipitate of tactoidal collagen formed as in Examples above. EXAMPLE 7 As for Example 6 except that PEG 4000 was added to a final concentration of 2.0% (w/v).
  • EXAMPLE 8 As for Example 1 except that PEG 1000 to a f ina l concentration of 5% (w/v ) was used to precipitate the collagen.
  • EXAMPLE 9 As for Example 1 except that PEG 10000 to a f ina l concentration of 5% (w/v ) wa s used to precipitate the collagen.
  • EXAMPLE 10 The suspension of tactoidal collagen from Example 1 was stored at 4°C for 4 weeks and collected on Whatman No. 1 filter paper in a 125 mm diameter basket centrifuge rotating at 4000 rpm. The resulting collagen sheet was removed from the centrifuge and separated from the filter paper.
  • the collagen sheet was found to have properties similar to those of a thick, wet paper tissue and to be suitable for assisting in the healing of open skin wounds.
  • EXAMPLE 11 The collagen sheet, prepared as in Example 10, was tanned using a solution of 0.01% glutaraldehyde for 18 hours. After drying the sheet was found to have a tensi l e strength of 6.2N/sq cm and an e l ongati on of 12% at a moisture content of 16%.
  • EXAMPLE 12 The collagen sheet, prepared as in Example 10 was sealed in a polyethylene bag and subjected to 2.5Mrads of gamma ray irradiation.
  • Example 14 As for Example 1 except that the collagen extracted from foetal calfskin was not purified by fraction salt precipitation but was used as a crude extract and that 5% PEG 4000 was used.
  • EXAMPLE 15 As for Example 14 except that 5% polyvinyl alcohol was used.
  • EXAMPLE 16 As for Example 14 except that 5% dextran of 10,000 average molecular weight was used.
  • EXAMPLE 17 As for Example 14 except that 5% dextran of 40,000 average molecular weight was used.
  • EXAMPLE 18 A collagen sheet prepared as in Example 10 was rolled into a tube and then stabilized by tanning using a solution of 0.01% glutaraldehyde for 18 hours.
  • EXAMPLE 19 A co l l agen sheet prepared as in Examp l e 10 was dried b y critical point drying using l iquid carbon dioxide.
  • Col lagen f ractionation Separation of native types I, II and III by dif ferential precipitation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

On obtient du collagène sous forme de tactoïdes en formant une solution aqueuse contenant du collagène dissous et un polymère miscible ou soluble dans l'eau destiné à permettre la précipitation du collagène hors de la solution sous la forme de tactoïdes.
PCT/AU1987/000038 1987-01-02 1987-02-12 Precipitation de collagene sous forme de tactoides WO1988006043A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR8707660A BR8707660A (pt) 1987-02-12 1987-02-12 Produtos de colagenio
BR8707169A BR8707169A (pt) 1987-01-02 1987-02-12 Produtos de colagenio
PCT/AU1987/000038 WO1988006043A1 (fr) 1987-02-12 1987-02-12 Precipitation de collagene sous forme de tactoides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/AU1987/000038 WO1988006043A1 (fr) 1987-02-12 1987-02-12 Precipitation de collagene sous forme de tactoides

Publications (1)

Publication Number Publication Date
WO1988006043A1 true WO1988006043A1 (fr) 1988-08-25

Family

ID=3762879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1987/000038 WO1988006043A1 (fr) 1987-01-02 1987-02-12 Precipitation de collagene sous forme de tactoides

Country Status (2)

Country Link
BR (1) BR8707660A (fr)
WO (1) WO1988006043A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264155A (en) * 1979-07-09 1981-04-28 Opticol Corporation Collagen contact lens
US4407787A (en) * 1980-10-03 1983-10-04 Dr. Ruhland Nachf. Gmbh Collagenous dressing
AU3380384A (en) * 1983-10-04 1985-04-18 Johnson & Johnson Protein/polysaccharide complexes as wound dressing
AU4701385A (en) * 1984-09-05 1986-03-13 Collagen Corporation A process for preparing malleable collagen and the product thereof
US4585797A (en) * 1981-04-13 1986-04-29 Seton Company Cosmetic and pharmaceutical sheet material containing polypeptides
AU5160285A (en) * 1984-12-24 1986-07-17 Collagen Corporation Collagen membranes for medical use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264155A (en) * 1979-07-09 1981-04-28 Opticol Corporation Collagen contact lens
US4407787A (en) * 1980-10-03 1983-10-04 Dr. Ruhland Nachf. Gmbh Collagenous dressing
US4585797A (en) * 1981-04-13 1986-04-29 Seton Company Cosmetic and pharmaceutical sheet material containing polypeptides
AU3380384A (en) * 1983-10-04 1985-04-18 Johnson & Johnson Protein/polysaccharide complexes as wound dressing
AU4701385A (en) * 1984-09-05 1986-03-13 Collagen Corporation A process for preparing malleable collagen and the product thereof
AU5160285A (en) * 1984-12-24 1986-07-17 Collagen Corporation Collagen membranes for medical use

Also Published As

Publication number Publication date
BR8707660A (pt) 1989-08-15

Similar Documents

Publication Publication Date Title
US4980403A (en) Collagen products
Feroz et al. Keratin-Based materials for biomedical applications
CA1295796C (fr) Matrice biodegradable et methode de production de la matrice
US20040266992A1 (en) Method for the preparation of silk fibron hydrogels
US6706684B1 (en) Method for preparing a collagen material with controlled in vivo degradation
US4969912A (en) Human collagen processing and autoimplant use
Wei et al. Hyaluronic acid hydrogels with IKVAV peptides for tissue repair and axonal regeneration in an injured rat brain
EP2976112B1 (fr) Améliorations de et associées à des matériaux à base de collagène
EP0296078A1 (fr) Nouveaux biomatériaux à base de mélanges de collagène, de chitosan et de glycosaminoglycanes, leur procédé de préparation ainsi que leurs applications en médecine humaine
CN114601958B (zh) 一种透明质酸/丝素蛋白双交联可注射水凝胶及其制备方法
AU2005291306B2 (en) Covalent grafting of hydrophobic substances on collagen
EP0674908A1 (fr) Implants à base de collagène présentant des qualités superieures de résistance à la traction
JPH0679616B2 (ja) 架橋化医用品
AU591964B2 (en) Collagen products
US20050214374A1 (en) Artificial extracellular matrix and process for producing the same
WO1988006043A1 (fr) Precipitation de collagene sous forme de tactoides
Sionkowska 11 Natural Polymers as
KR101282394B1 (ko) 콜라겐에 대한 소수성 물질의 공유 그래프팅법
Sionkowska 11 NC atural Polymers as omponents of Blends
CN116848132A (zh) 产生具有受控特性的人胶原蛋白结构的方法
JPH05105624A (ja) 強化コラーゲン線維膜及びその調製法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BR KR